Liver Disease
13 videos · updated daily
2:08 VISTAS 28-Week Results: Volixibat for PSC Itch
Dr Deepak Joshi discusses 28-week results from the VISTAS study of volixibat for itch in primary sclerosing cholangitis, presented at the British Association for the Study of the Liver annual meeting, for PSC Support.
13:06 Lipodystrophy Research Presented at ENDO 2026
Elif Oral, MD, of the University of Michigan reviews lipodystrophy research presented at ENDO 2026, including long-term metreleptin data and baseline results from the METRE-PL Phase 3 trial.
6:44 Maralixibat for Cholestatic Pruritus: Phase 3 EXPAND
Jennifer Vittorio, MD, of NYU Langone Health discusses for HCPLive findings from the Phase 3 EXPAND trial of maralixibat for cholestatic pruritus in ultra-rare liver diseases, including biliary atresia, alongside earlier EMBARK and BOLD results.
12:01 Noninvasive Testing and MASH Clinical Trials
Winston Dunn, MD, of the University of Kansas Medical Center tells Xtalks how noninvasive testing and risk-stratification tools could shape MASH clinical trials, why fibrosis may weigh more in trial design and how machine learning could aid risk assessment.
13:03 Designing Clinical Trials for Long COVID and ME/CFS
Dr. David Putrino of Mount Sinai's Cohen Center for Recovery from Complex Chronic Illness discusses collaborative trial design for Long COVID and ME/CFS, including a low-dose rapamycin trial for Long COVID that was under way in August 2026, for PolyBio.
56:55 PSC Treatments: Experts on Recent Trial Results
Professors Palak Trivedi, Michael Trauner and Andreas Kremer explain what recent clinical trial results mean for people with primary sclerosing cholangitis and map the road to effective treatments, for PSC Support.
2:32 VITALITY Trial of Oral Vancomycin in PSC-IBD
Professor Palak Trivedi and Martine Brown of PSC Support announce funding for VITALITY, an international multi-centre trial of oral vancomycin for people with primary sclerosing cholangitis and inflammatory bowel disease.
18:34 Clinical Trials 101 for Autoimmune Hepatitis
Kim Ruela, Vice President of Clinical Operations at Avant Santé, gives the Autoimmune Hepatitis Association an overview of what clinical trials are, why they matter, the phases and key terms, and what is involved in designing and running a trial.
14:56 Ultragenyx CYPRUS2+ Gene Therapy Trial in Wilson Disease
Eric Crombez, medical director at Ultragenyx, describes the CYPRUS2+ gene therapy study in Wilson disease, its timeline and its aim of restoring ATP7B function in the liver, in a study that was enrolling well-managed adults at the time.
57:21 Clinical Trials and the PORTOLA Trial in Autoimmune Hepatitis
Noreen R. Henig, MD, chief medical officer at Kezar Life Sciences, explains how clinical trials are designed and run and describes the PORTOLA trial (NCT05569759) of a potential treatment for autoimmune hepatitis.
52:08 Webinar Highlighting Oramed's Positive Phase 2 NASH Data
Professor Yaron Ilan, M.D., of Hebrew University-Hadassah Medical Center and Joel Neutel, M.D., of the Orange County Research Center discuss Oramed's Phase 2 data for ORMD-0801 in NASH.
3:10 Clinical Trials of Resmetirom to Treat Fatty Liver Disease
Resmetirom in the form of a pill could reverse the effects of Fatty Liver Disease by targeting the thyroid hormone in the liver to get rid of liver fat, according to this local news report.
18:14 Pharmacokinetics in Early-Phase Clinical Development
Dr. Toni Grant, Director of Pharmacokinetics at Dr. Vince Clinical Research, presents at ASCPT 2025 how PK analysis and modelling guide dose selection and study design in ascending-dose, renal and hepatic impairment and drug-drug interaction studies.